RIGL
Rigel Pharmaceuticals Inc
47.90$
-0.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.8% | -17.4% | -17.0% | 0.8% | 39.2% | 25.2% | -1.7% | 30.0% | 34.6% | 31.5% | 4.6% | 38.9% | 28.7% | |
| 1.0% | 0.8% | 1.4% | 1.7% | 1.1% | 1.0% | 1.1% | 0.6% | 0.9% | 0.9% | 1.0% | 1.1% | 1.0% | |
| 6.9% | 5.4% | 17.4% | 6.9% | 4.8% | 3.6% | 6.2% | 3.2% | 4.8% | 3.9% | 5.9% | 8.7% | 5.9% | |
| 7.9% | -24.7% | -7.1% | -4.5% | 11.0% | -3.8% | -30.1% | 7.2% | -10.6% | -4.8% | -21.1% | 14.7% | -4.2% | |
| 0.1% | 0.3% | 0.5% | 0.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| -4.2% | -19.2% | 1.1% | 29.7% | 6.9% | -18.9% | -19.8% | -22.9% | -47.8% | -36.3% | -13.6% | 22.2% | -17.7% | |
| – | – | – | – | – | – | 0.0% | 0.0% | – | – | -6.4% | 4.8% | – | |
| – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | – | – | -12.8% | -9.8% | – | |
| -3.1% | 1.4% | -8.5% | -2.0% | -17.8% | 2.5% | 0.9% | 0.4% | 6.1% | -6.5% | -18.6% | -14.9% | -8.3% | |
| -12.1% | -35.3% | -24.4% | 28.4% | 28.3% | 8.8% | -20.6% | 7.6% | -7.0% | -11.4% | -27.5% | 46.3% | 2.7% | |
| -4.8% | -17.4% | -17.4% | 0.2% | 39.2% | 25.1% | -1.7% | 30.0% | 34.6% | 31.5% | 4.6% | 38.9% | 28.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.